<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140907</url>
  </required_header>
  <id_info>
    <org_study_id>0954-222</org_study_id>
    <secondary_id>MK0954-222</secondary_id>
    <secondary_id>2005_053</secondary_id>
    <nct_id>NCT00140907</nct_id>
  </id_info>
  <brief_title>ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional
      therapy) will reduce the number of RT patients who experience histological lesions of chronic
      allograft nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2000</start_date>
  <completion_date type="Actual">January 1, 2005</completion_date>
  <primary_completion_date type="Actual">January 1, 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of chronic allograft nephropathy</measure>
    <time_frame>24 months post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">367</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium</intervention_name>
    <description>25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients With End Stage Chronic Renal Failure, Four To Eight Week After Receiving A
             First Or A Second Renal Transplant From A Dead Donor. In The Case Of A Second
             Transplant The Survival Of The First Graft Must Has Been 6 Month Or More

          -  Patients Must Have A Serum Creatinine * 2 At Visit 1 And 2. Results Must Be Within 25%
             Of Each Other. The Baseline Period May Be Extended Until Four More Weeks To Obtain An
             Additional Serum Creatinine If One Of The First Two Serum Creatinine Results Do Not
             Qualify

          -  Patients With Hypertension Must Have A Sitting Blood Pressure &lt; 200/110 Mmhg At The
             Time Of Randomization

          -  Normotensive Patients Must Have A Sitting Systolic Blood Pressure &gt;100 Mmhg At The
             Time Of Randomization

        Exclusion Criteria:

          -  Hyperimmunized Patients At The Transplant Time Or In The Previous 6 Month, With A Pra
             of 50 %

          -  Patients With Evidence Of Advanced Liver Disease

          -  Serum Potassium &lt;3.5 Or &gt;5.5 Meq/L

          -  History Of Allergy To Losartan

          -  Other Factors Which May Affect Participation (E.G., Significant Concurrent Or Life
             Limiting Disease Such As Cancer In The Last Five Year Except Skin Neoplasias, Mental
             Or Legal Incapacitation, Drug Or Alcohol Abuse Within The Last 2 Years, Extensive
             Travel Planned In The Next 3 Years, Investigative Drug Trial Within The Last 4 Weeks)

          -  Patients With Disseminated Or Localized Active Infectious Disease, At The Time Of
             Transplant

          -  Acute Graft Rejection In The Grade III Of Banff Classification

          -  Patients With Double-Transplant (Reno-Pancreatic)

          -  Patients With Heart Failure Or History Of Myocardial Infarction Requiring Ace
             Inhibitor Or Aiia Therapies. Presence Or Known History Of Hemodynamically Significant
             Obstructive Valvular Disease Or Hypertrophic Cardiomyopathy

          -  Renal Graft Artery Stenosis. An Eco-Doppler Test Must Be Performed In Order To Exclude
             A Graft Artery Stenosis

          -  Pregnant Or Nursing Women

          -  Chronic Use Of Nsaids

          -  Major Psychotropic Agents Such As Phenothiazines Are Not Permitted, Use Of Lithium Is
             Not Permitted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

